share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K:重大事件
美股sec公告 ·  04/25 16:41
Moomoo AI 已提取核心訊息
On April 23, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Michael T. Cullen, the Chairman of the Board of Directors. The agreement involved the sale of one share of Series A Preferred Stock to Cullen for $10, which closed on the same day. This Preferred Stock grants 90 million votes and is non-convertible, with no dividend rights or asset distribution rights, except in the case of a reverse stock split proposal. Additionally, Panbela Therapeutics announced that Nasdaq filed a Form 25 Notification of Removal from Listing on April 25, 2024, which will result in the delisting of the company's common stock. In response, the company has applied to list its common stock on the Chicago Board of Options Exchange (CBOE) and will maintain its OTCQB listing under the symbol 'PBLA' in the interim. Furthermore, due to the delisting, a special meeting initially scheduled for May 3, 2024, to vote on a reverse stock split has been postponed to May 28, 2024, with a new record date set for April 24, 2024.
On April 23, 2024, Panbela Therapeutics, Inc. entered into a material definitive agreement with Michael T. Cullen, the Chairman of the Board of Directors. The agreement involved the sale of one share of Series A Preferred Stock to Cullen for $10, which closed on the same day. This Preferred Stock grants 90 million votes and is non-convertible, with no dividend rights or asset distribution rights, except in the case of a reverse stock split proposal. Additionally, Panbela Therapeutics announced that Nasdaq filed a Form 25 Notification of Removal from Listing on April 25, 2024, which will result in the delisting of the company's common stock. In response, the company has applied to list its common stock on the Chicago Board of Options Exchange (CBOE) and will maintain its OTCQB listing under the symbol 'PBLA' in the interim. Furthermore, due to the delisting, a special meeting initially scheduled for May 3, 2024, to vote on a reverse stock split has been postponed to May 28, 2024, with a new record date set for April 24, 2024.
2024 年 4 月 23 日,Panbela Therapeutics, Inc. 與董事會主席邁克爾·卡倫簽訂了實質性的最終協議。該協議涉及以10美元的價格向卡倫出售一股A系列優先股,該股於當天收盤。該優先股授予9000萬張選票,不可兌換,沒有股息權或資產分配權,反向股票拆分提案除外。此外,Panbela Therapeutics宣佈,納斯達克於2024年4月25日提交了25號表格的除名通知,這將導致該公司的普通股退市。作爲回應,該公司已申請在芝加哥期權交易所(CBOE)上市其普通股,並將在此期間繼續以'PBLA'的代碼在OTCQB上市。此外,由於退市,原定於2024年5月3日舉行的反向股票拆分投票的特別會議已推遲至2024年5月28日,新的紀錄日期定爲2024年4月24日。
2024 年 4 月 23 日,Panbela Therapeutics, Inc. 與董事會主席邁克爾·卡倫簽訂了實質性的最終協議。該協議涉及以10美元的價格向卡倫出售一股A系列優先股,該股於當天收盤。該優先股授予9000萬張選票,不可兌換,沒有股息權或資產分配權,反向股票拆分提案除外。此外,Panbela Therapeutics宣佈,納斯達克於2024年4月25日提交了25號表格的除名通知,這將導致該公司的普通股退市。作爲回應,該公司已申請在芝加哥期權交易所(CBOE)上市其普通股,並將在此期間繼續以'PBLA'的代碼在OTCQB上市。此外,由於退市,原定於2024年5月3日舉行的反向股票拆分投票的特別會議已推遲至2024年5月28日,新的紀錄日期定爲2024年4月24日。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息